secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001711279-23-000003
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech receives 3-month FDA BLA review extension for B-VEC; new PDUFA date May 19, 2023
--------------------------------------------------------------------------------

- FDA extended PDUFA date for B-VEC (beremagene geperpavec) to May 19, 2023 due to major amendment from manufacturing info.
- FDA indicated no Advisory Committee meeting and no REMS program needed for B-VEC application.
- All pre-approval inspections of clinical sites and internal facilities completed successfully.
- Labeling discussions proposed for no later than April 20, 2023.
- CEO expresses disappointment but commits to working with FDA and continuing commercial readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000003/0001711279-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000003/krys-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer